We use our versatile Ambifect™ Fc-fusion protein platform to invent and develop a diverse pipeline of therapeutic candidates for indications in Animal Health.

We partner with Animal Health companies that can take our novel therapeutics to market and maintain close involvement with our partners in the development and manufacturing process.

Animal Health

candidate
indication
mechanism
partner
Discovery
Development
Pivotal Studies
Market
AKS-321d
Canine Diabetes
FcRn recycled insulin for
once-a-week dosing
Indication: Canine Diabetes
Pivotal Studies

AKS-321d is a once-a-week insulin therapy for dogs, intended to replace the current twice-a-day veterinary insulin treatments. Akston has partnered with Dechra Pharmaceuticals PLC to commercialize AKS-321d.

Patent Info
AKS-425c
Feline Diabetes
FcRn recycled insulin for
once-a-week dosing
Indication: Feline Diabetes
Pivotal Studies

AKS-425c is a once-a-week insulin therapy for cats, intended to replace the current twice-a-day veterinary insulin treatments. Akston has partnered with Dechra Pharmaceuticals PLC to commercialize AKS-425c.

Patent Info
AKS-548d
Canine Chronic Pain
Therapeutic vaccine against NGF
Indication: Canine Chronic Pain
Development

Akston has developed AKS-548d to address chronic pain in dogs caused by increased levels of nerve growth factor (NGF) that stimulate inflammation and increased sensitivity to pain.

Patent Info
AKS-197d
Canine Oncology
Growth factor receptor downregulation
Indication: Canine Oncology
Development
AKS-427c
Feline Oncology
Growth factor receptor downregulation
Indication: Feline Oncology
Development
AKS-559c
Feline Diabetes/Obesity
FcRn recycled GLP-1 for once-a-week dosing
Indication: Feline Diabetes/Obesity
Development
AKS-616d
Canine Oncology
Therapeutic vaccine against PD-L1
Indication: Canine Oncology
Development
AKS-631d
Canine Atopic Dermatitis
Therapeutic vaccine against IL-31
Indication: Canine Atopic Dermatitis
Development

Akston has developed the human versions of some of its Animal Health candidates.  Once these Human Health candidates have completed early in vivo testing, Akston makes them available for licensing to companies to advance their development to the IND-enabling and clinical study stages.

Human Health

candidate
indication
mechanism
partner
Discovery
Pre-Clinical
Phase I
Phase II
Phase III
Market
AKS-452
COVID-19 Vaccine
Induce and/or augment antibody titers
Indication: COVID-19 Vaccine
Phase III

Akston developed a room temperature stable, low-cost CoV-2 protein subunit vaccine based on the Ambifect™ Fc-fusion protein platform. We are seeking Emergency Use Authorization (EAU) in India for this vaccine, and for its ‘universal’ booster vaccine capability. In 2023, Akston licensed this patent to Vakston for continued development.

Patent Info
AKS-107
Human T1D Intervention
Interrupt insulin autoimmunity
Indication: Human T1D Intervention
Pre-Clinical

Akston has developed AKS-107, a designer Fc-insulin fusion protein, to interrupt the process leading to insulin autoimmunity. Akston partnered with the Helmsley Charitable Trust and the National Institutes of Health (NIH) in the early development stages. In 2023, Akston licensed this patent to Diamune, Inc. for continued development.

Patent Info
AKS-440
Human Weekly Insulin
FcRn recycled insulin for
once-a-week dosing
Indication: Human Weekly Insulin
Pre-Clinical

Akston has developed AKS-440, a novel human insulin candidate based on the Ambifect™ Fc-fusion protein platform, intended to be a once-a-week injectable diabetes therapy. It is currently in pre-clinical development.

Patent Info
AKS-130
Human Oncology
Disrupt insulin receptor signaling in cancer cells
Indication: Human Oncology
Pre-Clinical

Akston has developed AKS-130, an insulin-Fc fusion protein designed to lower blood glucose levels in order to target the tumor cell insulin receptors. It is currently in pre-clinical development.

Patent Info

Platform

Ambifect™ platform for all candidates

Process

Discovery to therapeutics